• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

B-po05-144 comparing sodium glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset atrial fibrillation and ischemic stroke
Given the susceptibility of patients with type 2 diabetes mellitus towards cerebrovascular complications, there is increasing research on the cerebrovascular-protective effects of novel anti-diabetic agents. However, few studies have compared sodium glucose cotransporter-2 inhibitor (SGLT2I) and dipeptidyl peptidase-4 inhibitor (DPP4I) in their effects on stroke and atrial fibrillation (AF).
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Sharen Lee, Jiandong Zhou, Xiansong Wang, Carlin Chang, Tong Liu, Dong Chang, Wing Tak Wong, William K.K. Wu, Bernard M.Y. Cheung, Gary Tse, Qingpeng Zhang Source Type: research

Anti-diabetic drugs for preventing atrial fibrillation: a new revolution?
Type 2 diabetes mellitus (DM) and atrial fibrillation (AF) are two of the great epidemics of our time. DM affects and estimated 8.5% of adults in the US1, and is associated with an increased risk of cardiovascular events, including AF.2 AF in turn affects an estimated up to 12.5% of adults over age 65 years in the US, decreases quality of life and increases the risks of heart failure, stroke and death 3,4. In 2015, the EMPA-REG OUTCOME randomized controlled trial (RCT), assessing a sodium glucose co-transporter 2 inhibitor (SGLT-2i), sparked interest in the therapeutic potential for oral anti-diabetic agents to reduce card...
Source: Heart Rhythm - April 7, 2021 Category: Cardiology Authors: William F. McIntyre, Jeff S. Healey Source Type: research

Antidiabetic drugs for preventing atrial fibrillation: A new revolution?
Type 2 diabetes mellitus (DM) and atrial fibrillation (AF) are 2 of the great epidemics of our time. DM affects an estimated 8.5% of adults in the United States1 and is associated with an increased risk of cardiovascular events, including AF.2 AF in turn affects up to an estimated 12.5% of adults older than 65 years in the United States, decreases quality of life, and increases the risks of heart failure, stroke, and death.3,4 In 2015, the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) randomized controlled trial (RCT), which assessed the sodium glucose c...
Source: Heart Rhythm - April 7, 2021 Category: Cardiology Authors: William F. McIntyre, Jeff S. Healey Tags: Editorial Commentary Source Type: research